Description: GI disorder treatments are redefining the France Radiofrequency Ablation Devices Market, with specialized ablations on the rise.

October 2025 marks a pivotal shift in the France Radiofrequency Ablation Devices Market, valued at USD 274.8 million in 2024 and forecasted to USD 578.8 million by 2035 with 7.01% CAGR from 2025-2035. Gastroenterology applications, at 18% share, are surging via RFA for colorectal polyps and varices, treating 180,000 cases yearly per SNFGE data. The 2025 GI Health Initiative's EUR 100 million push has integrated RFA in endoscopy suites across 400 centers, from Nice to Rennes, yielding 85% polyp eradication rates with minimal bleeding risks.

Single needle devices lead GI at 50% for endoscopic deliveries, while multiples handle larger lesions. Hospitals hold 58% end-user sway for complex cases, ASCs for routine screenings. High-frequency excels in mucosal ablations, low-frequency for submucosal depths.

Defining this trend, the gastroenterology uses include Boston Scientific's RF snare, enhancing precision. AngioDynamics reported 19% GI sales growth, tied to training hubs. Opportunities in combo endoscopy-RFA kits could expand to 25% share, offsetting skill shortages. This refocuses care, cutting colectomy needs by 30%.

Endo-RFA hybrids will pioneer GI advancements.

#gastroenterologyrfa #giablation #francegihealth #endoscopytech #digestivetreatments